🇺🇸 FDA
Patent

US 11872261

Lipoprotein targeting protease inhibitors and uses

granted A61KA61K38/005A61K38/07

Quick answer

US patent 11872261 (Lipoprotein targeting protease inhibitors and uses) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/005, A61K38/07, A61K38/08, A61K38/10